Innovent Biologics and Sanegene Bio Commence Phase I Clinical Trial for Hypertension siRNA Drug
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with...
HutchMed Establishes Global R&D Hub in Hong Kong Science Park to Accelerate Translational Medicine
HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced the establishment of a global research...
Walvax Biotechnology’s Bivalent HPV Vaccine Earns WHO Pre-Qualification Status
China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has achieved a significant milestone with its bivalent...
CR Sanjiu to Acquire Significant Stake in Tasly Pharmaceuticals in a Deal Valued at $870 Million
China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999), has announced its intention to conditionally purchase...
Akeso Biopharma Initiates Phase II Global Study for Ligafulimab in High-Risk MDS
China-based Akeso Biopharma (HKG: 9926) has reached a clinical milestone with the dosing of the...
Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter...
China’s NMPA Launches Pilot Programs in Beijing and Shanghai for Innovative Drug Approvals
The National Medical Products Administration (NMPA) of China has given the green light to Beijing...
China’s State Council Unveils Guidelines to Enhance Basic Medical Insurance System
In a bid to address the evolving healthcare needs of an aging population and a...
AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal
US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition...
Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Mexico
Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in the medical device industry...
Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...
Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...
Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered...
Suzhou Zelgen’s Jacktinib Tablets Achieve Positive Results in Phase II IPF Clinical Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
ImmuneOnco Biopharmaceuticals Strikes Licensing Deal with Instil Bio for Global Rights to Dual-Targeted Antibodies
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with...
Sino Biopharmaceutical’s Benmelstobart Files for New Indication in China for Advanced RCC Treatment
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...
AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...
Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
GSK’s Jemperli Receives EC Approval for Endometrial Cancer Treatment in Combination Therapy
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced that the European Commission...
Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia
China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the...